Spontaneous intracerebral hematomas (ICH) are the most deadly form of stroke. Treatment options include admission to a specialized stroke unit and treatment of hypertension in the acute stage. However, both of these options have exhibited limited effectiveness. The RICH biobank collects biomaterial (DNA, plasma, serum and PAXgene) from patients with spontaneous ICH at different times in the first week after the bleeding, in order to:
1) gain insight into the role of inflammation in the development of secondary brain damage;
2) be able to explore different anti-inflammatory drugs in an ex vivo model for potential effectiveness, determined by the macrophage cytokine production capacity;
3) evaluate the effect of anti-inflammatory drug treatment in a phase II trial on markers of systemic inflammation;
4) to evaluate the effect of minimally invasive neurosurgical defecation of ICH versus regular treatment in a phase III trial on markers of systemic inflammation.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched
26 November 2021The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.
read more
New Automated PBMC isolation method introduced in LMI.
21 September 2021The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.
read more
Health-RI, geared up to accelerate
21 September 2021The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.
read more
SUNRISE-CRC sub-biobank
21 September 2021The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.
read more
PRECISE sub-biobank
21 September 2021The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.
read more
Lysine Metabolism sub-biobank
21 September 2021Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.
read more